Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from FDA

Juul scores big win when FDA walks back marketing ban on its e-cigarette

The FDA announced that it would be rescinding its action against Juul due to new case law and the agency’s review of information

The Independent UK

Gene editing's next big targets

Scientists are pursuing advances to address the technology's limitations and stretch gene editing to treat different types of diseases, improve agriculture, livestock and more.

Axios

Structure Therapeutics vs. Viking Therapeutics: Which Weight-Loss Drug Stock Wins?

With weight-loss drugs gaining traction, which biopharma stock wins?

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

This Experimental Male Birth Control Works Even Better Than Expected

The treatment, known as NES/T, just completed its phase two clinical trial with flying colors.

Inverse

Rolling Backward

Plus: Hezbollah escalates, congestion pricing halted, the Didion-Dunne family feud, GIMBYism, and more...

Reason

FDA advisers urge targeting JN.1 strain in recipe for fall's COVID vaccines

Government advisers say it’s time to update the recipe for the COVID-19 vaccines Americans will receive in the fall

The Independent UK

3 Dividend Growth Stocks to Buy and Hold

These three dividend-paying growth stocks are worth a look at current levels as the odds rise for Fed rate cuts.

Barchart

Read news from The Economist, FT, and more,
with one subscription

FDA Advisers Overwhelmingly Oppose Approval of MDMA As a Psychotherapeutic Catalyst

The panel's recommendation, based on several concerns about two clinical trials, is a serious setback for a promising PTSD treatment.

Reason

FDA Declines Approval Of MDMA As Treatment For PTSD

The FDA panel voted 9-2 on whether it was effective and voted 10-1 on whether the proposed MDMA treatment is safe or if its benefits would outweigh the risks.

International Business Times

Federal judge blocks some rules on abortion pills in North Carolina

A federal judge has permanently blocked some efforts in North Carolina to restrict how abortion pills can be dispensed

The Independent UK

FDA panel votes against ecstasy for PTSD

It's a big setback for the effort to mainstream psychedelic drugs.

Axios

Up Over 700% YTD, Here's How Much Higher Analysts Think This Biotech Stock Can Rise

As the biotech industry rebounds from recent challenges, a favorable regulatory environment and groundbreaking scientific advancements are creating investment opportunities, particularly in companies with robust clinical pipelines and promising early-stage data.

Barchart

1 Penny Stock Where You Can Spend Less And Earn More

This tiny stock could soar more than 400%, according to Wall Street.

Barchart

Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medication

Federal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - US

What is SPF and how much sunscreen do you really need? Experts answer

Skin cancer is the most common cancer in the US and while sunscreen abounds in aisles, many aren’t applying it correctly

Axios

European sunscreens offer better protection, dermatologist says

A growing number of Americans have reason to question the safety and efficacy of U.S. sunscreens.

StockNews.com

3 Biotech Stocks With Potential Breakthroughs Emerging

The biotech industry's future is promising, driven by advanced technologies like AI and VR, the rising popularity of personalized treatments, and increased R&D spending. Let's analyze the investment prospects of biotech stocks Amgen (AMGN), United Therapeutics (UTHR), and Gilead Sciences (GILD) as potential breakthroughs emerge. Read more.

Barchart

This Surging Small-Cap Biotech Has One Very High-Profile Investor

Humacyte is a pre-revenue biotech company that has delivered outsized gains to shareholders in 2024. But is the small-cap stock a good buy right now?

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

3 Cathie Wood Biotech Stocks That Analysts Expect to Double

This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference for Wood's disruptive approach to investing, may find these stocks particularly compelling.

Axios

Landmark review spotlights challenge of judging psychedelic therapies

FDA advisers this week will scrutinize what could become the first approved psychedelic drug.

Android Central

Smart rings will stay niche until they add these missing features

Smart rings are getting more popular by the year, but there are a few things keeping them from really breaking into the mainstream. Here's my wishlist for what these smart rings could really use.

The Guardian - UK

Can psychedelics treat depression? Maybe, and you might not even have to take a trip

The use of the drugs in treating low mood has sparked debate, not least about the necessity of a hallucinogenic experience. But a new discovery may provide an answer

Reason

California's Tortilla Bill Threatens To Flatten Small Businesses

Proposed legislation mandates folic acid in masa flour, sparking fears among traditional tortilla makers about costs and cultural impact.

The Independent UK

The battle for MDMA as drug steps closer to becoming a prescription medicine

MDMA could be reclassified as a prescription medicine and made available to specially certified doctors and therapists

Medical Daily

Guillain-Barre Syndrome 'More Common Than Expected' In RSV Vaccinated Older Adults: CDC

While the U.S. Food and Drug Administration (FDA) and the officials from the CDC continue to investigate the risks, the current recommendation is to continue the vaccine as "the estimated benefits of RSV vaccination continued to outweigh potential risks."

1 … 98 99 100 101

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.